Newron completes screening for Phase 3 evenamide add-on trial in treatment-resistant schizophrenia

(AWP Alliance News) - Newron Pharmaceuticals reported completion of screening for enrollment in its pivotal Phase 3 ENIGMA-TRS 1 trial of evenamide as an add-on treatment for patients with treatment-resistant schizophrenia. Target enrollment of at least 600 patients is expected to be reached around mid-October, positioning the program for a key readout.

Topline results from the initial 12-week treatment period have not been presented yet and are expected in Q1 2027. The study is designed to determine whether evenamide can deliver a meaningful improvement in symptoms when added to existing antipsychotic therapy, with a focus on efficacy, safety, and tolerability over one year. The update keeps the company on track for a near-term data catalyst in a high unmet-need segment that could support a first-in-class add-on positioning if results are positive.

https://docs.publicnow.com/11C64DB54F3D3338CA2C33803D96EEF171A6D263

Disclaimer: This news brief was created using generative artificial intelligence. Newron Pharmaceuticals S.p.A. published the original content used to generate this news brief on September 02, 2026, and is solely responsible for the information contained therein.